samedan logo

 
 
spacer
home > pmps > winter 2021 > roundtable: pharmaceutical industry trends for 2021
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Roundtable: Pharmaceutical Industry Trends for 2021

Lynn Allen at MedPharm

When reflecting on 2020, itís clear that the pharma contract services market has demonstrated positive growth, even when we take into consideration the COVID-19 pandemic. Investment continued across the pharmaceutical industry, with the inclusion of large outsourcing contracts for vaccine production to address COVID-19, further driving the need for contract development services. In Q3 2020, an increased need for innovative solutions from the product development service sector was driven by the execution of 25 investment deals within the drug development market sector.

Another key area of focus is rare medical disorders, a welcoming trend to patients suffering from diseases with no treatment or pharmaceutical therapies. Due to the rarity of these conditions, they are manufactured in small quantities, with a goal of delivering patient-centric therapies to small groups of patients. As a result of convenience and affordability, topical formulation development delivery, which includes the eyes, skin, airways, or mucosal membranes, appears to be set to continue to increase in 2021, as it has done in recent years.

The pharma industry will maintain a shift to more specialised dosage forms for drug product development. Local delivery requires the formulation to pass through a barrier, such as the skin, the ophthalmic membrane, or the nasal cavity. These local delivery routes that work to minimise systemic effects, often associated with solid dose or injectable delivery routes, are becoming increasingly preferred in patient-centric drug product development. For these delivery routes, drug development expertise may not be found in-house, due to the specialised nature of these drugs. Outsourcing this custom development work to CROs and CDMOs, with a focus on unique drug delivery capabilities and technologies, offers experience to sponsors that can result in saving time and money over the development pathway.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.


spacer
Lynn Allen joined MedPharm as Vice President of Business Development in 2019. She is responsible for leading revenue growth, key client relationships, and marketing MedPharm to its global customer base. Prior to joining MedPharm, Lynn worked for DPT/Mylan and Jubilant Hollister-Stier. She has more than 25 years in sales and marketing, focusing on the contract services for sterile and non-sterile dosage forms. Lynn holds an MBA from University of Chicago, US.

Marcelo Cruz is Director, Business Development and Marketing at Tjoapack. With over a decade of experience in the pharma industry, and over 15 years of driving global strategic marketing and sales, Marcelo is responsible for the overall business development strategy and organic growth activities at Tjoapack. In his role, Marcelo also leads the development and implementation of inbound and outbound marketing strategies to accelerate lead generation and drive the wider commercial strategy for the business.

Tony OíSullivan is the Chief Commercial Officer for ChargePoint Technology. He has a wide range of responsibilities including overseeing direct and indirect sales channels, marketing, the technical product team, commercial activities, order delivery project management, and aftercare service support. As a member of the board, Tony also plays a key role in the planning and implementation of ChargePointís business plan to achieve strategic growth. For such a diverse role, his area of expertise in commercial and sales and marketing, plus project management, gives him the ability to see ChargePointís mission and vision like no other.

John S Ross has more than 20 yearsí experience in the contract services sector of the pharma industry. Prior to joining Mayne Pharma, John was a Principal at Tunnell Consulting, a leading US biotech and pharma consulting organisation. He has also held a number of leadership roles including Chief Operating Officer of Contract Pharmaceuticals Limited, a provider of outsourced third-party contract development, manufacturing, and testing of pharmaceuticals. John holds a Bachelor of Science and an MBA from the University of Western Ontario, Canada.
spacer
Lynn Allen
spacer
spacer
spacer
Marcelo Cruz
spacer
spacer
spacer
Tony O'Sullivan
spacer
spacer
spacer
John Ross
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

SPT Labtech acquires BioMicroLab

SPT Labtech, a global leader in the design and development of automated instrumentation and consumables for life science applications, announces the acquisition of BioMicroLab, a robotics automation provider for life science laboratories.
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement